Lansforsakringar Fondforvaltning AB publ Sells 3,187 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Lansforsakringar Fondforvaltning AB reduced its stake in Thermo Fisher Scientific Inc. by 2.5%, holding 123,705 shares valued at approximately $61.56 million as of the latest SEC filing.
• Analysts have mixed opinions on the stock, with Barclays raising its target price to $490.00 and Raymond James setting a higher target of $535.00, reflecting a generally positive outlook.
• Thermo Fisher Scientific reported a profit of $5.36 EPS, exceeding analysts' expectations, along with revenues of $10.86 billion for the recent quarter, indicating a 2.9% year-over-year growth.

Lansforsakringar Fondforvaltning AB publ lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,705 shares of the medical research company's stock after selling 3,187 shares during the period. Lansforsakringar Fondforvaltning AB publ's holdings in Thermo Fisher Scientific were worth $61,556,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the last quarter. Nuveen LLC bought a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $532,360,000. Farallon Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 73.8% in the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after buying an additional 523,800 shares during the last quarter. Sarasin & Partners LLP acquired a new position in Thermo Fisher Scientific in the first quarter valued at approximately $242,991,000. Finally, Two Sigma Advisers LP boosted its position in Thermo Fisher Scientific by 81.6% during the 4th quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after purchasing an additional 419,200 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,896 shares of company stock worth $13,603,438. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. HSBC restated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, UBS Group boosted their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $3.31 during mid-day trading on Friday, reaching $493.05. The company had a trading volume of 1,228,194 shares, compared to its average volume of 1,910,751. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $186.18 billion, a PE ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.74. The company has a 50-day moving average price of $452.50 and a two-hundred day moving average price of $454.32. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the previous year, the firm posted $5.37 EPS. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.